AIM: To determine the combined effect of very low nicotine content (VLNC) cigarettes and usual Quitline care [nicotine replacement therapy (NRT) and behavioural support] on smoking abstinence, in smokers motivated to quit. DESIGN: Single-blind, parallel randomized trial. SETTING: New Zealand. PARTICIPANTS Smokers who called the Quitline for quitting support were randomized to either VLNC cigarettes to use whenever they had an urge to smoke for up to 6 weeks after their quit date, in combination with usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support) or to usual Quitline care alone. MEASUREMENTS: The primary outcome was 7-day point-prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cigarette consumption, withdrawal, self-efficacy, alcohol use, serious adverse events and views on the use of the VLNC cigarettes at 3 and 6 weeks and 3 and 6 months. FINDINGS:A total of 1410 participants were randomized (705 in each arm), with a 24% loss to follow-up at 6 months. Participants in the intervention group were more likely to have quit smoking at 6 months compared to the usual care group [7-day point-prevalence abstinence 33 versus 28%, relative risk (RR) = 1.18, 95% confidence interval (CI): 1.01, 1.39, P = 0.037; continuous abstinence 23 versus 15%, RR = 1.50, 95% CI: 1.20, 1.87, P = 0.0003]. The median time to relapse in the intervention group was 2 months compared to 2 weeks in the usual care group (P < 0.0001). CONCLUSIONS: Addition of very low nicotine content cigarettes to standard Quitline smoking cessation support may help some smokers to become abstinent.
RCT Entities:
AIM: To determine the combined effect of very low nicotine content (VLNC) cigarettes and usual Quitline care [nicotine replacement therapy (NRT) and behavioural support] on smoking abstinence, in smokers motivated to quit. DESIGN: Single-blind, parallel randomized trial. SETTING: New Zealand. PARTICIPANTS Smokers who called the Quitline for quitting support were randomized to either VLNC cigarettes to use whenever they had an urge to smoke for up to 6 weeks after their quit date, in combination with usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support) or to usual Quitline care alone. MEASUREMENTS: The primary outcome was 7-day point-prevalence smoking abstinence 6 months after quit day. Secondary outcomes included continuous abstinence, cigarette consumption, withdrawal, self-efficacy, alcohol use, serious adverse events and views on the use of the VLNC cigarettes at 3 and 6 weeks and 3 and 6 months. FINDINGS: A total of 1410 participants were randomized (705 in each arm), with a 24% loss to follow-up at 6 months. Participants in the intervention group were more likely to have quit smoking at 6 months compared to the usual care group [7-day point-prevalence abstinence 33 versus 28%, relative risk (RR) = 1.18, 95% confidence interval (CI): 1.01, 1.39, P = 0.037; continuous abstinence 23 versus 15%, RR = 1.50, 95% CI: 1.20, 1.87, P = 0.0003]. The median time to relapse in the intervention group was 2 months compared to 2 weeks in the usual care group (P < 0.0001). CONCLUSIONS: Addition of very low nicotine content cigarettes to standard Quitline smoking cessation support may help some smokers to become abstinent.
Authors: Sarah S Dermody; Jennifer W Tidey; Rachel L Denlinger; Lauren R Pacek; Mustafa al'Absi; David J Drobes; Dorothy K Hatsukami; Ryan Vandrey; Eric C Donny Journal: Alcohol Clin Exp Res Date: 2016-02-25 Impact factor: 3.455
Authors: Melissa Mercincavage; E Paul Wileyto; Megan L Saddleson; Kirsten Lochbuehler; Eric C Donny; Andrew A Strasser Journal: Addiction Date: 2017-02-23 Impact factor: 6.526
Authors: Sarah S Dermody; F Joseph McClernon; Neal Benowitz; Xianghua Luo; Jennifer W Tidey; Tracy T Smith; Ryan Vandrey; Dorothy Hatsukami; Eric C Donny Journal: Exp Clin Psychopharmacol Date: 2018-03-05 Impact factor: 3.157
Authors: Melissa Mercincavage; Valentina Souprountchouk; Kathy Z Tang; Rachel L Dumont; E Paul Wileyto; Steven G Carmella; Stephen S Hecht; Andrew A Strasser Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-04-27 Impact factor: 4.254
Authors: Eric C Donny; Dorothy K Hatsukami; Neal L Benowitz; Alan F Sved; Jennifer W Tidey; Rachel N Cassidy Journal: Prev Med Date: 2014-06-23 Impact factor: 4.018
Authors: Rachel Isaksson Vogel; Louise A Hertsgaard; Sarah S Dermody; Xianghua Luo; Lor Moua; Sharon Allen; Mustafa al'Absi; Dorothy K Hatsukami Journal: Addict Behav Date: 2014-03-30 Impact factor: 3.913
Authors: Jason D Robinson; Francesco Versace; Jeffery M Engelmann; Yong Cui; David G Gilbert; Andrew J Waters; Ellen R Gritz; Paul M Cinciripini Journal: J Psychopharmacol Date: 2016-04-19 Impact factor: 4.153
Authors: Dorothy K Hatsukami; Louise A Hertsgaard; Rachel I Vogel; Joni A Jensen; Sharon E Murphy; Stephen S Hecht; Steven G Carmella; Mustafa al'Absi; Anne M Joseph; Sharon S Allen Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-19 Impact factor: 4.254
Authors: Dorothy K Hatsukami; Neal L Benowitz; Eric Donny; Jack Henningfield; Mitch Zeller Journal: Nicotine Tob Res Date: 2012-10-25 Impact factor: 4.244